SIHUAN PHARM (00460) expects a mid-term net profit of no less than 50 million yuan.

SIHUAN PHARM (00460) announced that the group is expected to achieve revenue of no less than RMB 1.1 billion and net profit of no less than RMB 50 million for the six months ending June 30, 2025. Factors affecting the group's financial performance during this period include: (1) high growth in the medical beauty business, with a growth rate of 50%-60% compared to the same period last year; (2) the innovative drug business entering the harvest period, with a gradual reduction in R&D expenses for innovative drugs, continuous emergence of approved new products, smooth commercialization progress of new products, and continuous growth in revenue for this segment; (3) the decreasing decline of the generic drug business year by year; (4) the company's solid financial condition with sufficient cash on hand. From January 2024 to the end of July 2025, the group has a total of 41 medical beauty and pharmaceutical new products approved and listed, including 9 medical beauty products such as the company's self-developed flagship products Girl Needle (brand name: Qianyan), Child Needle (brand names: Huuyanzhen and Svyen), and exclusive agency products such as the Sylfirm X dual-polar radiofrequency microneedle system, as well as 32 pharmaceutical new products including the company's self-developed innovative drug Pirosilin Tablet (brand name: Xuanyuening), Phenylalanine Glimepiride Tablets (brand name: Huiyouding), and the domestically produced first generic drug Degudemond Dual Insulin Injection (brand name: Huiyoujia), Degudemond Insulin Injection (brand name: Huiyouda) (including supplementary applications). The group expects that the simultaneous listing of so many flagship new products will bring strong momentum for the group's future revenue and profit growth, and the group is confident in its future development prospects.